1. Home
  2. TECH vs RVPH Comparison

TECH vs RVPH Comparison

Compare TECH & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bio-Techne Corp

TECH

Bio-Techne Corp

HOLD

Current Price

$59.83

Market Cap

9.2B

Sector

Health Care

ML Signal

HOLD

Logo Reviva Pharmaceuticals Holdings Inc.

RVPH

Reviva Pharmaceuticals Holdings Inc.

HOLD

Current Price

$0.29

Market Cap

71.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECH
RVPH
Founded
1976
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2B
71.0M
IPO Year
1989
N/A

Fundamental Metrics

Financial Performance
Metric
TECH
RVPH
Price
$59.83
$0.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
6
Target Price
$71.23
$3.33
AVG Volume (30 Days)
1.6M
8.4M
Earning Date
02-04-2026
11-13-2025
Dividend Yield
0.54%
N/A
EPS Growth
N/A
N/A
EPS
0.49
N/A
Revenue
$1,216,732,000.00
N/A
Revenue This Year
$2.33
N/A
Revenue Next Year
$7.05
N/A
P/E Ratio
$120.82
N/A
Revenue Growth
3.85
N/A
52 Week Low
$46.01
$0.25
52 Week High
$79.28
$2.17

Technical Indicators

Market Signals
Indicator
TECH
RVPH
Relative Strength Index (RSI) 50.87 30.55
Support Level $58.54 $0.27
Resistance Level $59.64 $0.34
Average True Range (ATR) 1.46 0.06
MACD 0.11 -0.04
Stochastic Oscillator 80.40 9.85

Price Performance

Historical Comparison
TECH
RVPH

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: